Drugs / Albuvirtide
Albuvirtide
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05206019 | Feb → Apr 2022 | AIDS | Frontier Biotechnologies Inc. | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary | ||||||
| Phase 2 | NCT04560569 | Nov 2021 → Nov 2022 | HIV infectious disease | Frontier Biotechnologies Inc. | Unknown | Met primary |
| Phase 2 | NCT04819347 | May 2021 → Jun 2022 | HIV infectious disease | Frontier Biotechnologies Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT03719664 | Dec 2018 → Dec 2022 | HIV infectious disease | Frontier Biotechnologies Inc. | Unknown | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT02369965 | Feb 2014 → Apr 2018 | AIDS | Frontier Biotechnologies Inc. | Completed | Met primary |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Albuvirtide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04560569 ↗ |
| Known as | FB-006M | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297257 ↗ |
| Known as | Labuvirtide | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297257 ↗ |
| Action | Inhibit | “a fusion inhibitor” PMID 41896772 ↗ Mar 2026 |
| Modality | Other / unclassified | “long-acting fusion inhibitor albuvirtide” PMID 33252379 ↗ Nov 2020 |
| Route | Intravenous | “administered intravenously once a week” NCT02369965 ↗ |